ArticleRheumatology international2020
Management of childhood-onset autoinflammatory diseases during the COVID-19 pandemic.
Article in Rheumatology international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- A Systematic Review of Characteristics Associated with COVID-19 in Children with Typical Presentation and with Multisystem Inflammatory Syndrome.International journal of environmental research and public health · 2021Pooled it
- A systematic review of the infectious complications of colchicine and the use of colchicine to treat infections.Seminars in arthritis and rheumatism · 2021Pooled it
- Haemodynamic implications of cardiovascular magnetic resonance pulmonary capillary wedge pressure in acute myocardial infarction.European heart journal. Imaging methods and practice · 2025Article
- Application of Interferon-γ Release Assay in the Assessment of T-Cell Immunity to SARS-CoV-2 Antigens in the Cohort of Pediatric Patients with Juvenile Idiopathic Arthritis.Children (Basel, Switzerland) · 2024Article
- Interferon-γ Release Assay in the Assessment of Cellular Immunity-A Single-Centre Experience with mRNA SARS-CoV-2 Vaccine in Patients with Juvenile Idiopathic Arthritis.Journal of clinical medicine · 2024Article
- Severity of SARS-CoV-2 infection in children with inborn errors of immunity (primary immunodeficiencies): a systematic review.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2023Article
- The impact of COVID-19 on clinical course and treatment among patients with juvenile systemic sclerosis.Archives of rheumatology · 2023Article
- Purpura Fulminans After Varicella Infection and Pulmonary Embolism After COVID-19 Infection in Familial Mediterranean Fever: Coincidence or Not?Turkish archives of pediatrics · 2023Article
- Colchicine - From rheumatology to the new kid on the block: Coronary syndromes and COVID-19.Cardiology journal · 2023Review
- Early impacts of the COVID-19 pandemic on children with pediatric rheumatic diseases.European journal of rheumatology · 2022Article
- Clinical impact and disease evolution of SARS-CoV-2 infection in familial Mediterranean fever.Pharmacological research · 2022Article
- [Colchicine, an old friend's perspectives for rheumatology in COVID-19: a scoping review].Revista colombiana de reumatologia · 2022Review
- Comparisons of Clinical Features and Outcomes of COVID-19 between Patients with Pediatric Onset Inflammatory Rheumatic Diseases and Healthy Children.Journal of clinical medicine · 2022Article
- Therapeutic role of immunomodulators during the COVID-19 pandemic- a narrative review.Postgraduate medicine · 2022Review
- COVID-19 Vaccination Intention and Vaccine Hesitancy among Patients with Autoimmune and Autoinflammatory Rheumatological Diseases: A Survey.International journal of clinical practice · 2022Article
- Central nervous system manifestations of monogenic autoinflammatory disorders and the neurotropic features of SARS-CoV-2: Drawing the parallels.Frontiers in pediatrics · 2022Review
- Immunologic Dysregulation and Hypercoagulability as a Pathophysiologic Background in COVID-19 Infection and the Immunomodulating Role of Colchicine.Journal of clinical medicine · 2021Review
- COVID-19 Pandemic and Patients with Rare Inherited Metabolic Disorders and Rare Autoinflammatory Diseases-Organizational Challenges from the Point of View of Healthcare Providers.Journal of clinical medicine · 2021Article
- Clinical features and outcomes of 76 patients with COVID-19-related multi-system inflammatory syndrome in children.Clinical rheumatology · 2021Article
- Impact of COVID-19 on Pediatric Immunocompromised Patients.Pediatric clinics of North America · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Concerns regarding the comorbidity as a significant risk factor for Coronavirus Disease-2019 (COVID-19), gave rise to an urgent need for studies evaluating patients with chronic conditions such as autoinflammatory diseases (AIDs). We prepared a web-based survey investigating the clinical findings and contact histories among pediatric patients with AIDs. Confirmed COVID-19 cases, patients with contact history and those with symptoms which were highly suggestive of COVID-19 were called via phone or recruited to a video or face to face appointment. Data of AIDs were obtained from their medical records, retrospectively. Laboratory and screening findings were confirmed by our national health registry website. There were 404 patients (217 female) eligible for the enrollment. During pandemic, 375 (93%) were on colchicine treatment and 48 (11.8%) were receiving biologic treatment. Twenty-four out of 404 patients were admitted to hospital due to COVID-19 suspicion. Severe acute respiratory syndrome coronavirus-2 (SARS CoV-2) was identified through rhinopharyngeal swabs in seven patients, six of whom were only on colchicine treatment. Only one patient with no finding of any severe respiratory complications was hospitalized. All of seven patients recovered completely. Among patients on biologic drugs, neither a symptom nor a positive polymerase chain reaction test for COVID 19 was detected. In conclusion, pediatric patients with AIDs, those receiving biologic treatment and/or colchicine, may not be at increased risk for neither being infected nor the severe disease course.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.